Pacific Biosciences of California, Inc.
PACB- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- SEC CIK
- 0001299130
In the last 90 days, Pacific Biosciences of California, Inc. insiders filed 0 open-market purchases and 1 sale; 223 institutions reported holding it in 13F filings for Q2 2026, worth $320.8M in total; superinvestors ARK Invest and HHLR Advisors (Hillhouse) hold it.
13F holders, Q3 2023
Institutional positions in Pacific Biosciences of California, Inc. as of Sep 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 275
- +4 vs. Q2 2023
- Shares held
- 261.6M
- +7.89M (+3.1%) vs. Q2 2023
- Total value
- $2.20B
- −$1.18B (−34.9%) vs. Q2 2023
- New holders
- 43
- 92 more added
- Sold out
- 39
- 86 more reduced
1 institution that held it in Q2 2023 haven't filed for Q3 2023 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q2 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting PACB on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 223 | $320.8M |
| Q1 2026 | 231 | $248.5M |
| Q4 2025 | 216 | $373.5M |
| Q3 2025 | 208 | $237.8M |
| Q2 2025 | 207 | $245.8M |
| Q1 2025 | 225 | $265.6M |
| Q4 2024 | 227 | $475.1M |
| Q3 2024 | 226 | $394.3M |
| Q2 2024 | 229 | $331.9M |
| Q1 2024 | 268 | $1.01B |
| Q4 2023 | 274 | $2.76B |
| Q3 2023 | 275 | $2.20B |
| Q2 2023 | 272 | $3.37B |
| Q1 2023 | 260 | $2.93B |
| Q4 2022 | 237 | $1.84B |
| Q3 2022 | 227 | $1.23B |
| Q2 2022 | 230 | $1.03B |
| Q1 2022 | 250 | $2.03B |
| Q4 2021 | 256 | $4.20B |
| Q3 2021 | 246 | $4.83B |
| Q2 2021 | 261 | $6.04B |
| Q1 2021 | 263 | $5.47B |
Institutions, Q3 2023
Shares, value and share of portfolio for each institution holding Pacific Biosciences of California, Inc.; share changes are against Q2 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BSW Wealth Partners | 0 | $0 | 0.00% | −11,415−100.0% | Sold out |
| Bayesian Capital Management, LP | 0 | $0 | 0.00% | −10,836−100.0% | Sold out |
| Quantitative Investment Management, LLC | 0 | $0 | 0.00% | −10,417−100.0% | Sold out |
| AXS Investments LLC | 0 | $0 | 0.00% | −5,845−100.0% | Sold out |
| Harbor Investment Advisory, LLC | 0 | $0 | 0.00% | −3,899−100.0% | Sold out |
| Fairfield, Bush & Co. | 0 | $0 | 0.00% | −2,000−100.0% | Sold out |
| State of Wyoming | 0 | $0 | 0.00% | −406−100.0% | Sold out |
| TD Waterhouse Canada Inc. | 0 | $0 | 0.00% | −225−100.0% | Sold out |
| Impact Partnership Wealth, LLC | 0 | $0 | 0.00% | −136−100.0% | Sold out |
| Gradient Investments LLC | 0 | $0 | 0.00% | −60−100.0% | Sold out |
| Versant Capital Management, Inc | 0 | $0 | 0.00% | −48−100.0% | Sold out |
| Disciplined Investments, LLC | 0 | $0 | 0.00% | −8−100.0% | Sold out |
| Capital Advisors, Ltd. LLC | 0 | $0 | 0.00% | −13−100.0% | Sold out |
| Ronald Blue Trust, Inc. | 0 | $0 | 0.00% | −34−100.0% | Sold out |
| Pictet Asset Management SA | – | – | – | – | Not filed |